APTORUM GROUP LTD. news, videos and press releases
For more news please use our advanced search feature.
APTORUM GROUP LTD. - More news...
APTORUM GROUP LTD. - More news...
- Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
- Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
- Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
- Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
- Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023
- Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange
- Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman
- Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report
- Aptorum Group to Hold Investor Webinar and Q&A Session with President on May 19
- Aptorum Group Limited to Present at the Infectious Disease Virtual Conference
- Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update
- Aptorum Group Limited to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020
- Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform
- Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference
- Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
- Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants
- Aptorum Group Announces Pricing of $10 Million Registered Direct Offering
- Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
- Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
- Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020
- Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
- Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA
- Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019
- Smart Pharma Token (SMPT) Debuts Its Initial Listing On IDAX: Global Blockchain Cryptocurrencies Trading Exchange Platform
- USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations
